Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HKSE:02135's PB Ratio is ranked better than 90.98% of 610
companies
in the Healthcare Providers & Services industry
Industry Median: 1.97
vs HKSE:02135: 0.57
During the past 12 months, Raily Aesthetic Medicine International Holdings's average Book Value Per Share Growth Rate was 7.00% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -17.80% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -17.10% per year.
During the past 9 years, the highest 3-Year average Book Value Per Share Growth Rate of Raily Aesthetic Medicine International Holdings was 132.80% per year. The lowest was -23.90% per year. And the median was 4.25% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Raily Aesthetic Medicine International Holdings PB Ratio Related Terms
Raily Aesthetic Medicine International Holdings PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Raily Aesthetic Medicine International Holdings PB Ratio Chart
Raily Aesthetic Medicine International Holdings Annual Data
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Raily Aesthetic Medicine International Holdings PB Ratio vs Healthcare Providers & Services Industry
Raily Aesthetic Medicine International Holdings PB Ratio Calculation
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Raily Aesthetic Medicine International Holdings (HKSE:02135) has a PB Ratio of 0.56 as of Aug. 21, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Raily Aesthetic Medicine International Holdings and its competitors. This is 56% below median its historical median of 1.27. Over the past decade, Raily Aesthetic Medicine International Holdings' PB Ratio has ranged from 0.31 to 8.49. According to the industry distribution chart, Raily Aesthetic Medicine International Holdings ranks #55 out of 610 companies in the Healthcare Providers & Services industry, placing it in the top 9%.
Is Raily Aesthetic Medicine International Holdings' PB Ratio too high?
Raily Aesthetic Medicine International Holdings' current PB Ratio of 0.56 is 56% below median its 10-year median of 1.27. Over the past 10 years, this metric has ranged from a low of 0.31 to a high of 8.49. The Healthcare Providers & Services industry median PB Ratio is 1.97. Raily Aesthetic Medicine International Holdings' value of 0.56 is 71.6% below this industry median. Based on the distribution chart, Raily Aesthetic Medicine International Holdings ranks #55 out of 610 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Raily Aesthetic Medicine International Holdings has a GF Score™ of 47/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Raily Aesthetic Medicine International Holdings' PB Ratio compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Raily Aesthetic Medicine International Holdings ranks #55 out of 610 companies for PB Ratio. This places Raily Aesthetic Medicine International Holdings in the top 9% of its industry — outperforming the majority of peers. The industry median PB Ratio is 1.97. Raily Aesthetic Medicine International Holdings' value of 0.56 is 71.6% below this benchmark. Historically, Raily Aesthetic Medicine International Holdings' own PB Ratio has ranged from 0.31 to 8.49 over the past decade. While the company's 10-year median is 1.27 vs. the industry median of 1.97, Raily Aesthetic Medicine International Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Healthcare Providers & Services company?
The median PB Ratio among Healthcare Providers & Services companies is 1.97, based on 610 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Raily Aesthetic Medicine International Holdings's current PB Ratio of 0.56 is 71.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Raily Aesthetic Medicine International Holdings and its competitors. For the Healthcare Providers & Services industry, the median PB Ratio is 1.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Raily Aesthetic Medicine International Holdings's current PB Ratio is 0.56, which is 56% below median its own 10-year median of 1.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Raily Aesthetic Medicine International Holdings stock overvalued right now?
Based on GuruFocus' analysis, Raily Aesthetic Medicine International Holdings (HKSE:02135) is currently considered Modestly Undervalued. The stock's GF Value™ is HK$0.14, compared to a current price of HK$0.12 — trading 15% below its estimated fair value. The current PB Ratio is 0.56, which is 56% below median its 10-year median of 1.27 and 71.6% below the Healthcare Providers & Services industry median of 1.97. Raily Aesthetic Medicine International Holdings' overall GF Score™ is 47/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Raily Aesthetic Medicine International Holdings (HKSE:02135), the current PB Ratio is 0.56 as of Aug. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Raily Aesthetic Medicine International Holdings (HKSE:02135) Overvalued in 2026?
Based on GuruFocus' analysis, Raily Aesthetic Medicine International Holdings stock appears to be undervalued.
The current stock price of HK$0.12 is trading 15% below its estimated GF Value™ of HK$0.14.
GuruFocus considers Raily Aesthetic Medicine International Holdings to be Modestly Undervalued.
Key valuation signals for HKSE:02135:
PB Ratio: 0.56 (56% below median its 10-year median of 1.27)
GF Value™: HK$0.14 vs. price of HK$0.12 (15% below fair value)
Industry Position: 71.6% below the Healthcare Providers & Services median (#55 of 610)
No single metric tells the full story. See the HKSE:02135 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Raily Aesthetic Medicine International Holdings Ltd is an investment holding company. The company were principally engaged in the provision of aesthetic medical services, sale of aesthetic medical equipment products and provision of consulting services. The group is organized into three reportable operating segments namely Aesthetic medical services comprise principally inpatient services including surgical services and outpatient services including injection service, dermatology service and others; Aesthetic medical equipment products comprise principally sales of collagen injection products, surgical implants and aesthetic medical skincare products; Consulting services comprise principally management consulting services of which majority of revenue comes from Aesthetic medical services.
47GF Score
Get the complete analysis for HKSE:02135
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02135 has been successfully added to your 
